Valuation: Scancell Holdings plc

Market Cap 114M 150M 134M 125M 215M 14.56B 216M 1.51B 589M 7.4B 565M 553M 23.8B P/E 2026 *
-6.32x
P/E 2027 * -3.81x
Enterprise Value 124M 164M 147M 137M 234M 15.89B 236M 1.65B 643M 8.08B 617M 603M 25.98B EV / Sales 2026 *
99.5x
EV / Sales 2027 * 56.2x
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -
1 day-0.53%
1 month-4.08%
3 months-36.27%
6 months-18.26%
Current year-5.05%
1 week 9.3
Extreme 9.3
9.6
1 month 9.3
Extreme 9.3
10.55
Current year 9.3
Extreme 9.3
29.5
1 year 9.1
Extreme 9.1
29.5
3 years 7.26
Extreme 7.26
29.5
5 years 7.26
Extreme 7.26
29.5
10 years 0.11
Extreme 0.1118
29.5
Manager TitleAgeSince
Chief Executive Officer 69 28/07/2021
Chief Executive Officer 64 18/11/2024
Director of Finance/CFO 50 24/04/2026
Director TitleAgeSince
Director/Board Member 69 17/11/2010
Director/Board Member 74 23/10/2019
Director/Board Member 64 24/09/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/09/25
Vulpes Investment Management Pte Ltd.
BuyCompany 3,150,000 0.3038%
08/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 102,236 0.0099%
04/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 4,400,000 0.4244%
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%0.00%-3.59%-36.27% 152M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-1.16%+23.36%+79.34% 58.81B
+0.17%-1.16%+3.59%+34.55% 48.45B
+0.50%-2.14%+331.33%+688.65% 42.84B
-0.72%-3.99%+28.50%+29.35% 42.79B
+0.34%-0.52%+6.56%+110.67% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
-0.50%-3.10%-10.19%-12.86% 24.05B
Average +0.00%-0.28%+47.31%+106.65% 39.44B
Weighted average by Cap. +0.53%-0.54%+55.82%+128.83%

Financials

2026 *2027 *
Net sales 1.25M 1.65M 1.48M 1.38M 2.35M 160M 2.37M 16.54M 6.46M 81.22M 6.2M 6.06M 261M 2.31M 3.05M 2.72M 2.54M 4.35M 295M 4.38M 30.53M 11.93M 150M 11.44M 11.2M 482M
Net income -19.23M -25.4M -22.7M -21.18M -36.22M -2.46B -36.5M -254M -99.41M -1.25B -95.36M -93.3M -4.02B -27.94M -36.9M -32.97M -30.76M -52.62M -3.57B -53.02M -370M -144M -1.82B -139M -136M -5.84B
Net Debt 10.42M 13.76M 12.29M 11.47M 19.62M 1.33B 19.76M 138M 53.84M 677M 51.65M 50.53M 2.18B 15.79M 20.85M 18.63M 17.38M 29.73M 2.02B 29.95M 209M 81.59M 1.03B 78.27M 76.57M 3.3B
Projected Income Statement - Annual - Scancell Holdings plc
Logo Scancell Holdings plc
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
Employees
60
Date Price Change Volume
07/10/26 GBX 9.400 -0.53% 1,289,532
06/10/26 GBX 9.450 +0.53% 4,319,405
05/10/26 GBX 9.400 -1.05% 924,430
02/10/26 GBX 9.500 +1.60% 1,881,946
01/10/26 GBX 9.350 -0.53% 1,350,349
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Scancell Holdings plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0945GBP
Average target price
0.2550GBP
Spread / Average Target
+169.84%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Scancell Holdings plc
  1. Stock Market
  2. Stocks
  3. SCLP Stock